Vallabh Janardhan: Vascular Disease Is Ultimately A Story of Thrombosis
Vallabh Janardhan, Co-Founder and CMO at Insera Therapeutics, Inc., shared on LinkedIn:
”Dallas CV Updates 2026 reinforced something I’ve been thinking about increasingly: vascular disease is ultimately a story of thrombosis.
From coronary plaque rupture to embolic stroke to venous thromboembolism, the final common pathway is clot biology.
A particularly compelling discussion this year centered on Lipoprotein(a) by Dr. Shahzeb Khan — not only as an atherogenic particle, but as a pro-thrombotic contributor that may amplify clot formation across vascular beds.
As our understanding deepens, prevention and intervention are no longer separate conversations.
Credit to Dr. Srini Potluri and Dr. Robert Smith for convening a forum that blends clinical excellence with forward-looking discussion at Baylor Scott and White The Heart Hospital.
Always energizing to engage with colleagues shaping the next phase of cardiovascular care in Dallas and beyond.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 14:29Joseph Caprini: The Future of VTE Care Is Shifting from Static Risk to Digital Twins
-
Apr 15, 2026, 14:25Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
-
Apr 15, 2026, 14:16Erin VanDyke: Next Generation Is Leading the Way in Pediatric VTE Care
-
Apr 15, 2026, 14:13Shahzeb Hassan: Pulmonary Embolism – What to Do When Every Minute Matters
-
Apr 15, 2026, 14:06Hossam El Benawi: Intensive Blood Pressure Reduction May Worsen Outcomes After Thrombectomy
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia